🐦 推特Wall St EngineCodex · 实盘不做把握 5/10
北京时间·🕒 发布 18:32:48时区推断·⟳ 抓取 18:32:57·⚡ 决策 08-04 18:48:08 +15m11s·84.1 天前
IDEXX二季度业绩超预期并小幅上调全年EPS指引
公司官方披露Q2收入12.17亿美元、同比增长10%，EPS为4.27美元、同比增长18%，均高于市场预期。
📄 原文Wall St Engine@wallstengine↗ 原文
IDEXX $IDXX Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $1.22B (Est. $1.2B) 🟢; +10% YoY 🔹 EPS: $4.27 (Est. $3.94) 🟢; +18% YoY…
不做 IDEXX Laboratories（IDXX.US）
不做：业绩和EPS好于预期但属于已知财报日历事件，全年收入和EPS指引上调幅度有限，对约450亿美元市值公司的短线重估弹性不足；等开盘真实承接或电话会新增指引后再由新信号判断。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- IDEXX正式发布Q2 2026业绩，确认收入、EPS、CAG增长和全年指引上调。市场反应:发布时美股常规盘尚未开盘，本轮未取得可靠实时盘前成交价。
- 社交账号在官方发布后约2分钟转述业绩亮点，说明扩散刚开始但不是首发。
关键理由
- 公司官方披露Q2收入12.17亿美元、同比增长10%，EPS为4.27美元、同比增长18%，均高于市场预期。
- 全年EPS指引上调至14.69-14.94美元，但相对前次中点仅提高0.14美元，收入指引中点仅上调约500万美元，增量偏小。
- 这是已知财报日历内的盘前业绩披露，核心利好更像优质成长确认而非短线市值级重估催化。
主要风险
- 若开盘前电话会进一步上调需求、毛利率或资本回报预期，可能重新形成交易窗口。
- 若盘前已明显跳空，当前这种有限指引上修更容易出现高开后兑现。
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-08-04 · 影响 weakens
官方表格显示收入指引中点仅较前次提高约500万美元，EPS中点仅提高0.14美元，削弱短线追多弹性。
检索:IDEXX Q2 2026 guidance prior updated revenue EPS midpoint 原文 ↗
原文全文
展开原文 · 1,056 字
IDEXX $IDXX Q2’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $1.22B (Est. $1.2B) 🟢; +10% YoY
🔹 EPS: $4.27 (Est. $3.94) 🟢; +18% YoY
🔹 Operating Margin: 35.0%; +140 bps YoY
🔹 CAG Diagnostics Recurring Revenue: $974.7M; +11% YoY
Raises FY26 Guide:
🔹 FY26 Revenue: $4.70B-$4.75B (Est. $4.71B) 🟡
🔹 FY26 EPS: $14.69-$14.94 (Est. $14.65) 🟢
🔹 FY26 Operating Margin: 32.3%-32.5%
Segment Net Revenue:
🔹 CAG: $1.12B; +9.4% YoY
🔹 Water: $58.6M; +14.8% YoY
🔹 LPD: $35.2M; +10.8% YoY
Other Q2 Metrics:
🔹 Organic Revenue Growth: 9%
🔹 CAG Diagnostics Recurring Revenue: $974.7M; +11% YoY
🔹 Gross Margin: 64.0%; +140 bps YoY
Comments:
🔸 “Our second quarter results reflect the strength of our Technology for Life strategy, with continued innovation across our Catalyst, Fecal Dx, and IDEXX inVue Dx platforms supporting deeper customer adoption and higher diagnostic utilization.”
🔸 “This is the kind of durable, compounding growth we're building for the long term, helping veterinarians see more and do more for their patients while creating lasting value for our shareholders.”
🔹 Revenue: $1.22B (Est. $1.2B) 🟢; +10% YoY
🔹 EPS: $4.27 (Est. $3.94) 🟢; +18% YoY
🔹 Operating Margin: 35.0%; +140 bps YoY
🔹 CAG Diagnostics Recurring Revenue: $974.7M; +11% YoY
Raises FY26 Guide:
🔹 FY26 Revenue: $4.70B-$4.75B (Est. $4.71B) 🟡
🔹 FY26 EPS: $14.69-$14.94 (Est. $14.65) 🟢
🔹 FY26 Operating Margin: 32.3%-32.5%
Segment Net Revenue:
🔹 CAG: $1.12B; +9.4% YoY
🔹 Water: $58.6M; +14.8% YoY
🔹 LPD: $35.2M; +10.8% YoY
Other Q2 Metrics:
🔹 Organic Revenue Growth: 9%
🔹 CAG Diagnostics Recurring Revenue: $974.7M; +11% YoY
🔹 Gross Margin: 64.0%; +140 bps YoY
Comments:
🔸 “Our second quarter results reflect the strength of our Technology for Life strategy, with continued innovation across our Catalyst, Fecal Dx, and IDEXX inVue Dx platforms supporting deeper customer adoption and higher diagnostic utilization.”
🔸 “This is the kind of durable, compounding growth we're building for the long term, helping veterinarians see more and do more for their patients while creating lasting value for our shareholders.”
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。